A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Insufficiency

Interventions

DRUG: LY3841136

Sponsor

Eli Lilly and Company